It is estimated that at least 12% of diabetic patients suffer from diabetic macular edema, one of the major complications of this population.
There are more than 415 million people in the world with diabetes, and Colombia is believed to have nearly 4 million, of which only 60% are diagnosed. In it World Diabetes Day, November 14Companies such as Bayer are seeking to raise awareness about the major damage that this blindness can bring about.
Currently, diabetes mellitus (DM) is considered a global epidemic and is the third cause of irreversible blindness. It is caused by diabetic macular edema (DME), which is one of the main effects of diabetes, and affects 12% of patients.
Dr Juan Gonzalo Sánchez, President of the Colombian Retina and Vitreous Association, says that EMD affects the macula located in the center of the retina. This field of vision is what allows us to choose high-resolution vision, for example, to distinguish faces, to read and control. Visual problems associated with this pathology arise when fluid passes from the blood vessels that accumulate in the retina and affects the macula, causing swelling or thickening. "
Symptoms of EMD
The macular edema of the diabetes is usually painless and may begin to show some symptoms, mainly blurred vision, loss of visual contrast and patches, but should be treated with time to avoid irreversible degenerative changes. Being a quiet disease, attention should be paid to blood pressure, glucose and cholesterol levels. Similarly, the higher the level of diabetes in patients, the greater the chance of developing EMD.
"This disease is one of the biggest complications in diabetic patients because of the risk of loss of vision, although it is not painful, it is early diagnosed and treated in a timely manner to reduce eye loss," says Liliana Torres, a medical consultant who offers innovative therapy for visual analysis of Bayer Colombia .
Dr. Juan Gonzalo Sánchez recently led a review of the literature titled "Anti-Vegf Therapy for the Treatment of Retinal Diseases: a Recommendation for the Practice of Columbia" published in the Journal of the Columbia Ophthalmology Association, which deals with the treatment that has been developed by the Columbia Ophthalmology Association in conjunction with various specialist academic and public and private care centers for special retinas. inhibits endothelial growth factor.This review, which was conducted for the first time in the country, emphasizes the importance of managing EMD, which has an optimal blood glucose control, blood pressure and lipid control to avoid retinal complications.
Dr. Gonzalo says that the management of these patients is fragmented, that "the care of these people is passed on to general ophthalmologists, optometrists or endocrinologists and, finally, the retinologist treats them for loss of vision, which suggests that there is no multidisciplinary leadership in controlling the disease."
In various complications, the retina has several treatment methods, but the success of control is based on multidisciplinary management, which complements the various treatments with continuous review.
Dr Torers adds that "we are currently working on a number of awareness-raising activities for diabetic patients to conduct eye examinations to diagnose a disease early in order to prevent EMD development."
Acorev acknowledges that there are various medical options in Colombia that can be robust enough to use treatments that can combat EMD, but there are not enough studies that can exacerbate the current state of diabetes patients.